ALX Oncology Holdings Inc. (ALXO) earnings
ALXO earnings moved a median of +2.48% by the close. Quarterly and annual ALXO reports and results, each read against the price at its own news timestamp. Back to the ALXO overview →
24 measured ALXO earnings events.
Where these ALXO earnings landedvs 23 measured ALXO earnings reactions
| Middle 50% of ALXO earnings reactions | -6.45% to +9.41% |
|---|---|
| Median reaction (to close) | +2.48% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 ALXO earnings events with a measured close landed between -6.45% and +9.41%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -2.01% | +8.76% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30 | SEC filing · Form 10-Q | -1.90% | -0.47% | |
| ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.59% | +10.05% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Mar 31 | SEC filing · Form 10-Q | -1.59% | +10.05% | |
| Form 10-K ALX ONCOLOGY HOLDINGS For: Dec 31 | SEC filing · Form 10-K | +1.83% | — | |
| ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.01% | +14.05% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Sep 30 | SEC filing · Form 10-Q | +0.79% | +0.00% | |
| ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting | Press release | +0.32% | -1.27% | |
| ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.18% | +6.55% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30 | SEC filing · Form 10-Q | -0.18% | +6.55% | |
| ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | Press release | -3.26% | +15.23% | |
| ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -5.43% | -7.40% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Mar 31 | SEC filing · Form 10-Q | -0.93% | -11.17% | |
| ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | Press release | +3.46% | +2.48% | |
| Form 10-K ALX ONCOLOGY HOLDINGS For: Dec 31 | SEC filing · Form 10-K | -3.44% | -13.82% | |
| ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.29% | -6.45% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Sep 30 | SEC filing · Form 10-Q | -1.29% | -6.45% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30 | SEC filing · Form 10-Q | +2.03% | +7.32% | |
| ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.82% | -4.75% | |
| ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.91% | -7.37% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Mar 31 | SEC filing · Form 10-Q | -0.91% | -7.37% | |
| Form 10-K ALX ONCOLOGY HOLDINGS For: Dec 31 | SEC filing · Form 10-K | +1.35% | +8.18% | |
| ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +3.13% | +14.97% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Sep 30 | SEC filing · Form 10-Q | +3.13% | +14.97% |
Keep exploring
More ALXO: analyst actions → · SEC filings → · ALXO overview →